Gonorrhea screening: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
Line 4: Line 4:


==Overview==
==Overview==
The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection. Currently available evidence is insufficient to assess the balance of benefits and harms of screening for gonorrhea in [[heterosexual]] men. USSTF recommends at least annual screenings for gonorrhea among men who have sex with men (MSM).<ref name=STD-guildline>{{cite web | title = 2015 Sexually Transmitted Diseases Treatment Guidelines (CDC) | url = http://www.cdc.gov/std/tg2015/screening-recommendations.htm }}</ref><ref name=Gonorrhea-recomm>Workowski KA, Bolan GA. Sexually transmitted diseases treat- ment guidelines, 2015. MMWR Recomm Rep 2015;64:60–68.</ref><ref name=USPSTF>US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016</ref>
The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection. Currently available evidence is insufficient to assess the balance of benefits and harms of screening for gonorrhea in [[heterosexual]] men. USSTF recommends at least annual screenings for gonorrhea among men who have sex with men (MSM).


==Screening==
==Screening==
The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.
The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.
The table below outlines the screening recommendations for gonorrhea.<ref name=STD-guildline>{{cite web | title = 2015 Sexually Transmitted Diseases Treatment Guidelines (CDC) | url = http://www.cdc.gov/std/tg2015/screening-recommendations.htm }}</ref><ref name=Gonorrhea-recomm>Workowski KA, Bolan GA. Sexually transmitted diseases treat- ment guidelines, 2015. MMWR Recomm Rep 2015;64:60–68.</ref><ref name=USPSTF>US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016</ref>
The table below outlines the screening recommendations for gonorrhea.<ref name="STD-guildline">{{cite web | title = 2015 Sexually Transmitted Diseases Treatment Guidelines (CDC) | url = http://www.cdc.gov/std/tg2015/screening-recommendations.htm }}</ref><ref name="Gonorrhea-recomm">Workowski KA, Bolan GA. Sexually transmitted diseases treat- ment guidelines, 2015. MMWR Recomm Rep 2015;64:60–68.</ref><ref name="USPSTF">US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016</ref><ref name="urlGonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines">{{cite web |url=https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm |title=Gonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines |format= |work= |accessdate=}}</ref>


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|+
|+
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 500px;" | {{fontcolor|#FFF|Screening Recommendations}}
! style="background: #4479BA; width: 500px;" |{{fontcolor|#FFF|Screening Recommendations}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Women'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''Women'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Sexually active women under 25 years of age
*Sexually active women under 25 years of age
* Sexually active women age 25 years and older if at increased risk
*Sexually active women age 25 years and older if at increased risk
**Prior history of sexually transmitted infection
**Prior history of sexually transmitted infection
**A new sex partner
**A new sex partner
Line 25: Line 25:
**A sex partner who has a sexually transmitted infection
**A sex partner who has a sexually transmitted infection
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Men Who have Sex With Men (MSM)'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''Men Who have Sex With Men (MSM)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* At least annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use
*At least annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use
* Every 3 to 6 months if at increased risk
*Every 3 to 6 months if at increased risk
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Pregnant women'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''Pregnant women'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*All pregnant women under 25 years of age and older women if at increased risk
*All pregnant women under 25 years of age and older women if at increased risk
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''HIV positive patients'''
| style="padding: 5px 5px; background: #DCDCDC;" |'''HIV positive patients'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* For sexually active individuals, screen at first HIV evaluation, and at least annually  
*For sexually active individuals, screen at first HIV evaluation, and at least annually
* More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology
*More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology
|}
|}


Latest revision as of 19:52, 21 August 2021

Sexually transmitted diseases Main Page

Gonorrhea Microchapters

Home

Patient Info

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Gonorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Antibiotic Resistance

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gonorrhea screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gonorrhea screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gonorrhea screening

CDC on Gonorrhea screening

Gonorrhea screening in the news

Blogs on Gonorrhea screening

Directions to Hospitals Treating Gonorrhea

Risk calculators and risk factors for Gonorrhea screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]

Overview

The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection. Currently available evidence is insufficient to assess the balance of benefits and harms of screening for gonorrhea in heterosexual men. USSTF recommends at least annual screenings for gonorrhea among men who have sex with men (MSM).

Screening

The U.S. Preventive Services and Task Force (USSTF) recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection. The table below outlines the screening recommendations for gonorrhea.[1][2][3][4]

Population Screening Recommendations
Women
  • Sexually active women under 25 years of age
  • Sexually active women age 25 years and older if at increased risk
    • Prior history of sexually transmitted infection
    • A new sex partner
    • More than one sex partner
    • A sex partner with concurrent partners
    • A sex partner who has a sexually transmitted infection
Men Who have Sex With Men (MSM)
  • At least annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use
  • Every 3 to 6 months if at increased risk
Pregnant women
  • All pregnant women under 25 years of age and older women if at increased risk
HIV positive patients
  • For sexually active individuals, screen at first HIV evaluation, and at least annually
  • More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology

References

  1. ↑ "2015 Sexually Transmitted Diseases Treatment Guidelines (CDC)".
  2. ↑ Workowski KA, Bolan GA. Sexually transmitted diseases treat- ment guidelines, 2015. MMWR Recomm Rep 2015;64:60–68.
  3. ↑ US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016
  4. ↑ "Gonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines".


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Gonorrhea_screening&oldid=1711803"